Newron Pharmaceuticals S.p.A. (NWRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
40 Pages - GLDATA51009
$250.00

Summary

Newron Pharmaceuticals S.p.A (Newron) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system (CNS) disorders and pain. Newron’s lead product safinamide is used in the the treatment of Parkinson’s disease (PD) It has many other pipeline products such as safinamide sNN0031 for the treatment of PD; ralfinamide for neuropathic pain; sNN0029 for the treatment of amyotrophic lateral sclerosis (ALS) ; sarizotan for Rett syndrome; NW-3509 for the treatment of schizophrenia; and ion channel projects. The company has partnerships with companies such as Zambon and Meiji Seika Pharma Co., Ltd. It carries out its research and development activities in Italy, the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals S.p.A. (NWRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Licensing Agreements 13
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 13
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 15
Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 17
Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 19
Equity Offering 21
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 21
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 23
Newron Pharma to Raise Funds through Public Offering of Shares 25
Newron Pharma Announces Private Placement Of Shares For US$21 Million 26
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 28
Newron Pharma Completes Private Placement Of US$3.64 Million 30
Acquisition 32
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 32
Biotie Therapies Terminates Acquisition Of Newron Pharma For US$60.5 Million 34
Santhera Pharma Terminates Acquisition Of Newron Pharma 36
Newron Pharmaceuticals S.p.A. - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Newron Pharmaceuticals S.p.A., Deals By Therapy Area, 2010 to YTD 2016 8
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 13
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 15
Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 17
Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 19
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 21
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 23
Newron Pharma to Raise Funds through Public Offering of Shares 25
Newron Pharma Announces Private Placement Of Shares For US$21 Million 26
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 28
Newron Pharma Completes Private Placement Of US$3.64 Million 30
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 32
Biotie Therapies Terminates Acquisition Of Newron Pharma For US$60.5 Million 34
Santhera Pharma Terminates Acquisition Of Newron Pharma 36
Newron Pharmaceuticals S.p.A., Key Competitors 37
Newron Pharmaceuticals S.p.A., Key Employees 38
Newron Pharmaceuticals S.p.A., Subsidiaries 39

List of Figures
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Newron Pharmaceuticals S.p.A., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838